Literature DB >> 23411597

Cisplatin-induced ototoxicity and the role of pharmacogenetic testing.

Lauren E Wyatt1, Mary Jayne Kennedy.   

Abstract

Entities:  

Keywords:  cisplatin; ototoxicity; pharmacogenetics; thiopurine S-methyltransferase (TPMT)

Year:  2012        PMID： 23411597      PMCID： PMC3567893          DOI： 10.5863/1551-6776-17.4.395

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN： 1551-6776


× No keyword cloud information.
  20 in total

Review 1.  Mechanisms of cisplatin-induced ototoxicity and prevention.

Authors:  Leonard P Rybak; Craig A Whitworth; Debashree Mukherjea; Vickram Ramkumar
Journal:  Hear Res       Date:  2006-11-17       Impact factor: 3.208

2.  Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose.

Authors:  Y Li; R B Womer; J H Silber
Journal:  Eur J Cancer       Date:  2004-11       Impact factor: 9.162

3.  Cisplatin ototoxicity in children: a practical grading system.

Authors:  P R Brock; S C Bellman; E C Yeomans; C R Pinkerton; J Pritchard
Journal:  Med Pediatr Oncol       Date:  1991

4.  Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration.

Authors:  G S Waters; M Ahmad; A Katsarkas; G Stanimir; J McKay
Journal:  Ear Hear       Date:  1991-04       Impact factor: 3.570

Review 5.  Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale.

Authors:  Penelope R Brock; Kristin R Knight; David R Freyer; Kathleen C M Campbell; Peter S Steyger; Brian W Blakley; Shahrad R Rassekh; Kay W Chang; Brian J Fligor; Kaukab Rajput; Michael Sullivan; Edward A Neuwelt
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

6.  Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development.

Authors:  Kristin R Gilmer Knight; Dale F Kraemer; Edward A Neuwelt
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

7.  Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system.

Authors:  W Stöhr; T Langer; A Kremers; S Bielack; A Lamprecht-Dinnesen; E Frey; J D Beck
Journal:  Cancer Invest       Date:  2005       Impact factor: 2.176

Review 8.  The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics.

Authors:  Howard L McLeod; Chokkalingam Siva
Journal:  Pharmacogenomics       Date:  2002-01       Impact factor: 2.533

9.  Left-right asymmetry in hearing loss following cisplatin therapy in children--the left ear is slightly but significantly more affected.

Authors:  Claus-Michael Schmidt; Arne Knief; Agatha Katharina Lagosch; Dirk Deuster; Antoinette am Zehnhoff-Dinnesen
Journal:  Ear Hear       Date:  2008-12       Impact factor: 3.570

Review 10.  Therapy for osteosarcoma: where do we go from here?

Authors:  Alexander J Chou; David S Geller; Richard Gorlick
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022
View more
  2 in total

Review 1.  Prevention and restoration of hearing loss associated with the use of cisplatin.

Authors:  Felician Chirtes; Silviu Albu
Journal:  Biomed Res Int       Date:  2014-07-22       Impact factor: 3.411

Review 2.  Lack of predictive tools for conventional and targeted cancer therapy: Barriers to biomarker development and clinical translation.

Authors:  Nikolaos Batis; Jill M Brooks; Karl Payne; Neil Sharma; Paul Nankivell; Hisham Mehanna
Journal:  Adv Drug Deliv Rev       Date:  2021-06-27       Impact factor: 15.470
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.